Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CDC25C | P30307 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437909 | 0.98 | MEN1 (0.63) | MEN1KMT2ARAD51CYP1A2MGLL | |
| SCHEMBL15437731 | 0.89 | RAD51 (0.69) | MEN1KMT2ARAD51CYP1A2MGLL | |
| SCHEMBL15437773 | 0.89 | MEN1 (0.53) | MEN1KMT2ARAD51CYP1A2MGLL | |
| SCHEMBL15437956 | 0.87 | MEN1 (0.60) | MEN1KMT2ARAD51MGLLITGA4 | |
| SCHEMBL15437696 | 0.87 | MEN1 (0.51) | MEN1KMT2ARAD51MGLLFAAH | |
| SCHEMBL15438309 | 0.86 | MEN1 (0.54) | MEN1KMT2ARAD51CYP1A2MGLL | |
| SCHEMBL14777408 | 0.84 | NR1H2 (0.53) | MEN1KMT2ARAD51MGLLFAAH | |
| SCHEMBL15437774 | 0.83 | KMT2A (0.47) | MEN1KMT2ARAD51MGLLITGA4 | |
| SCHEMBL16089518 | 0.83 | KMT2A (0.47) | MEN1KMT2ARAD51CYP1A2MGLL | |
| SCHEMBL15437791 | 0.80 | RAD51 (0.58) | MEN1KMT2ARAD51MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | claimed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | claimed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | claimed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | SOST, MYD88, MSR1 | MEN1 325/4885KMT2A 2720/4885RAD51 1883/4885 |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | SOST, MYD88, MSR1 | MEN1 508/4885KMT2A 2691/4885RAD51 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.